Isoxazole pyrazoloindane derivatives as cognition enhancing GABAA α5 subtype ligands
申请人:Merck Sharp & Dohme Ltd.
公开号:US07060710B2
公开(公告)日:2006-06-13
The present invention provides compounds of formula I:
in which:
one of X and Y is a nitrogen atom substituted by a group R6′ and the other is a carbon atom substituted by an isoxazole group substituted on its carbon atoms by groups R3 and R4;
one of R6 and R6′ is hydrogen;
either all of W1, W2, W3 and W4 are carbon or one of W1, W2, W3 and W4 is nitrogen and the rest are carbon;
and R1 and R2 are, independently, a small group, heteroaromatic ring or a 4–7 membered cyclic amine ring; processes for making them; pharmaceutical composition containing them; their use in therapy, particularly for enhancing cognition in conditions such as Alzheimer's Disease; and methods of treatment using them.
本发明提供了公式I的化合物:其中:X和Y中的一个是被R6'基取代的氮原子,另一个是被R3和R4基团取代的异噁唑基团取代的碳原子;R6和R6'中的一个是氢;W1、W2、W3和W4中的所有基团均为碳,或其中一个是氮,其余为碳;R1和R2是独立的小基团、杂环芳香环或4-7个成员的环状胺基团;制备它们的方法;含有它们的药物组合物;它们在治疗中的用途,特别是在阿尔茨海默病等认知增强方面的应用;以及使用它们的治疗方法。